Join our daily newsletter At The Bell to receive exclusive market insights
- Vection Technologies’ (VR1) has tabled a joint venture agreement for the launch of its new healthcare and pharmaceutical solutions division
- Following extensive negotiations, an agreement has been reached which will see Dr Carlo Centemeri and Vection receive a 40 per cent and 60 per cent interest in the new branch respectively
- Vection is set to front establishment costs of the division, which seeks to develop innovative educational and communication models in various healthcare market segments
- The decision comes just over a week after Vection launched the faction
- Vection Technologies is up 6.06 per cent on the market, trading at 10.5 cents per share
Vection Technologies’ (VR1) has tabled a joint venture agreement for the launch of its new healthcare and pharmaceutical solutions division.
Following extensive negotiations, Vection has secured “strong commitments” from the new division’s leader and company chief executive officer, Dr Carlo Centemeri, through the incorporation of a proposed joint venture.
The update comes just over a week after Vection launched the new faction, which will seek to develop innovative educational and communication models in various healthcare market segments.
Under the agreement, Dr Carlo Centemeri has secured a Managing Director position and 40 per cent interest in the branch, while Vection will retain the 60 per cent remaining controlling interest.
Vection is also set to front establishment costs of the division pursuant to a
comprehensive business plan underpinned by Dr Carlo’s commitment.
The new managing director is currently a Medical Science Senior Advisor to the Italian Ministry of Health and an Adjunct Professor of Pharmacology at three universities in Italy.
Vection Technologies is up 6.06 per cent on the market, trading at 10.5 cents per share at 2:50 pm AEDT.
